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adenocarcinoma: East versus WestBased on the American College of Gastroenterology guide-
lines, Barrett’s esophago (BE) is defined as a change in the
distal esophageal epithelium that can be recognized as
columnar type mucosa at endoscopy and is histologically
confirmed to have intestinal metaplasia. The development
of BE has also been associated with gastroesophageal reflux
disease (GERD). Other risk factors related to BE include
smoking, age, male gender, etc. Helicobacter pylori
infection has been reported to be negatively associated
with BE [1]. As a consequence of the clinical and epide-
miological evidence supporting the association between BE
and esophageal adenocarcinoma (EAC), BE is considered a
precancerous lesion of EAC. Based on that definition, the
prevalence of BE in Asia ranges from 0.06% to 6.2% [1]. The
reported prevalence of BE in Western countries has varied
from 0.9% to 4.5% in the general population and from 6.3%
to 13.6% in patients with GERD [2].
Wang et al [3] conducted a retrospective study which
collected 425 cases with BE, and of these, 15 cases with
EAC. This study aimed to investigate the clinical charac-
teristics and risk of EAC in patients with BE. Most of the
patients with EAC (14/15) underwent EGD due to alarming
symptoms that included heart burn, acid regurgitation,
dysphagia, and gastrointestinal bleeding. Among 15 pa-
tients with EAC, BE and EAC were diagnosed simultaneously
on first EGD for 14 cases with the 15th case having high
grade dysplasia. However, most of them were of late
stages. This study emphasized the importance of screening
EGDs for patients with alarming symptoms (which offer
significant clues in making the diagnosis of EAC). However,
due to lack of a comprehensive endoscopic surveillance
protocol for BE, no early EAC or high grade dysplasia could
be detected during the follow-up period in this study.
The incidences of EAC have been increasing rapidly since
the 1970s in most Western countries such as the UK, USA,
Australia, etc. This has led to the incidences of EAC
exceeding the incidences for esophageal squamous cell
carcinoma in these countries [2,4]. The risk factors of EAC
included BE, GERD, age, male gender, body mass index, and
tobacco smoking [2,5,6]. H. pylori infection has a negativehttp://dx.doi.org/10.1016/j.aidm.2015.04.006
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creativecommons.org/licenses/by-nc-nd/4.0/).association with development of EAC, however, the mech-
anism is unclear [7]. BE has been regarded as the most
important factor leading to EAC, and it is closely related to
GERD. Patients with BE have a 30- to 60-fold risk relative to
the general population in developing EAC [2,5]. The overall
risk of EAC development in patients with BE is estimated to
be approximately 0.12e0.5% per year [8e10]. Therefore,
regular endoscopic surveillance has been recommended
for BE to detect the occurrence of EAC in Western
countries.
In Asia, although an increasing incidence of GERD has
been noted in recent years, BE and EAC remain rare [11e13].
Currently, squamous cell carcinoma accounts for the ma-
jority of esophageal cancer. Based on the trend from
epidemiologic data generated from Western countries, it is
expected that incidence of BE in Asia could rise and EAC
might be more common in the future. However, the 5-year
survival rate for EAC is poor. How to make an early diagnosis
of EAC to improve the overall survival is a critical issue.
Endoscopic therapies such as radiofrequency ablation,
endoscopic mucosal resection, and endoscopic submucosal
dissection have been proven to be efficacious for the treat-
ment of early EAC or BE with dysplasia in many studies from
Western countries. Therefore, more prospective studies
focusing on endoscopic screenings for patients with UGI
alarming symptoms and endoscopic surveillance for patients
with BE are necessary to provide stronger evidence in Asia.
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